Bright Minds Biosciences (DRUG) Shares Outstanding (Weighted Average) (2020 - 2026)

Bright Minds Biosciences has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $266.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 86983107.71% year-over-year to $266.7 million; the trailing twelve-month figure through Mar 2026 stood at $266.7 million (up 86983107.71% YoY), and the FY2025 full-year result was $89.6 million, up 71865016.16% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $266.7 million, up from $98.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $266.7 million in Q1 2026, with the low at $7.16 in Q4 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $27.5 million across 5 years, with a median of $1176.2 in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) plunged 100.0% — and 2025, when it surged 1370084217.74%.
• Bright Minds Biosciences' Shares Outstanding (Weighted Average) stood at $478.86 in 2022, then surged by 589342.1% to $2.8 million in 2023, then sank by 100.0% to $7.16 in 2024, then surged by 1370084217.74% to $98.1 million in 2025, then surged by 171.96% to $266.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $266.7 million (Q1 2026), $98.1 million (Q4 2025), and $89.6 million (Q3 2025), per Business Quant data.